Anti-HBV Envelope Antigen Monoclonal Antibody, clone N1182032

Aim: Hepatitis B virus (HBV) infection is an important risk factor for morbidity and mortality in the general population. However, limited data are available on the progression of HBV infection in patients with end-stage renal disease (ESRD), and available data are controversial. Therefore, we investigated the association between hepatitis B surface antigen (HBsAg) seropositivity and mortality in patients with incident ESRD. Methods: All adult patients (>= 18 years of age) starting dialysis for ESRD from January 2000 to December 2011 were included. A total of 1090 patients with ESRD were analyzed. HBsAg-positive patients were paired 1: 6 with HBsAgnegative patients using propensity score matching. Results: Eighty one (7.4%) patients were HBsAg positive. No differences in the survival rates of the HBsAg-positive and HBsAg-negative patients with ESRD were detected in either the entire cohort or the propensity score matched cohort. No differences in survival were detected between the groups of HBsAgpositive patients based on the hepatitis B envelope antigen, hepatitis B envelope antibody, HBV DNA status, or use of antiviral agents. No difference in mortality was found between the haemodialysis (HD) and peritoneal dialysis (PD) subgroups among HBsAg-positive patients. Conclusion: Our results suggest that hepatitis B surface antigenaemia is not related to increased mortality in patients with incident ESRD. Survival of HBsAg-positive patients undergoing PD was comparable to that of patients undergoing HD.

Preliminary evidence of cases of acute occult hepatitis B virus (HBV) infection (OBI) has been recently reported in the literature. Furthermore, OBI definition has been the object of an international consensus conference. A case of acute primary OBI was identified and followed up in a repeat female blood donor using a highly sensitive nucleic acid test (NAT; Procleix Ultrio on Tigris, Chiron). Genotyping and sequencing of virus isolates from donor and contact cases were performed. The blood donor never developed detectable hepatitis B surface antigen (HBsAg) until seroconversion to antibody to hepatitis B surface antigen/antibody to hepatitis B core antigen. A very low viral load was observed during the infection course (< 50 IU/mL). Donor HBV DNA sequencing consistently showed a CCA deletion leading to amino acid T116 deletion in the small envelope protein (S). Other sequence features showed high homology between donor and contact case, suggesting a sexual transmission. The main explanation for HBsAg undetectability relies on the very low level of viremia observed. The single-amino-acid deletion found in the S protein cannot account for HBsAg detection failure, because the capture antibody of the assay used is targeted to a different sequence epitope (aa121-124). Meanwhile, CCA deletion may have impacted the virus replication efficiency since it affects the overlapping reverse transcriptase "finger" domain of the polymerase gene. These findings define this case as an acute primary OBI, confirming the existence of this condition. NAT with high sensitivity is the only screening enabling prevention of HBV transmission by transfusion in such cases.